Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.64 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497824 | 1.00 | FOLH1 (0.64) | FOLH1GSRSLC6A5RNPEPCA1 | |
| SCHEMBL1006179 | 1.00 | FOLH1 (0.64) | FOLH1GSRSLC6A5RNPEPCA1 | |
| SCHEMBL3832821 | 0.94 | FOLH1 (0.56) | FOLH1GSRSLC6A5RNPEPCA1 | |
| SCHEMBL20395062 | 0.94 | FOLH1 (0.56) | FOLH1GSRSLC6A5RNPEPCA1 | |
| SCHEMBL3832820 | 0.94 | FOLH1 (0.56) | FOLH1GSRSLC6A5RNPEPCA1 | |
| SCHEMBL28210617 | 0.91 | FOLH1 (0.55) | FOLH1GSRSLC6A5RNPEPCA1 | |
| SCHEMBL12461743 | 0.87 | GNPAT (0.52) | FOLH1GNPAT | |
| SCHEMBL43995 | 0.86 | FOLH1 (0.66) | FOLH1GSRSLC6A5RNPEPCA1 | |
| SCHEMBL12572609 | 0.86 | FOLH1 (0.83) | FOLH1GSRSLC6A5RNPEPCPB2 | |
| SCHEMBL43996 | 0.86 | FOLH1 (0.66) | FOLH1GSRSLC6A5RNPEPCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200095275-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABELS | KRANTZ ALEXANDER (US) | 2020-03-26 | — | — | US | claimed |
| EP-3506999-A1 | OPEN-PORE MEMBRANE HAVING AN INNER SPACE-SPANNING POLYMERIC STRUCTURAL NETWORK FOR ELECTROPHORETIC MATERIAL-SELECTIVE SEPARATION AND METHODS FOR PRODUCING AND USING SAME | Drei Lilien PVG GmbH & Co. KG (DE) | 2019-07-10 | — | — | EP | claimed |
| WO-2018042060-A1 | OPEN-PORE MEMBRANE HAVING AN INNER SPACE-SPANNING POLYMERIC STRUCTURAL NETWORK FOR ELECTROPHORETIC MATERIAL-SELECTIVE SEPARATION AND METHODS FOR PRODUCING AND USING SAME | DREI LILIEN PVG GMBH & CO. KG (DE) | 2018-03-08 | — | — | WO | claimed |
| US-20110201947-A1 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2011-08-18 | — | — | US | claimed |
| EP-2268305-A2 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | The Cleveland Clinic Foundation (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009114875-A2 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2009-09-17 | — | — | WO | claimed |
| CN-1946416-A | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window | KENNETH S WARREN INST INC (US) | 2007-04-11 | — | — | CN | claimed |
| CN-1897960-A | Tissue protective cytokines for protection, restoration, and enhancement of responsive cells, tissues and organs with extended therapeutic window | KENNETH S WARREN INST INC (US) | 2007-01-17 | — | — | CN | claimed |
| US-20240301469-A1 | MODIFYING, SEPARATING AND DETECTING PROTEOFORMS | NAUTILUS SUBSIDIARY, INC. | 2024-09-12 | — | — | US | disclosed |
| WO-2024177827-A1 | MODIFYING, SEPARATING AND DETECTING PROTEOFORMS | NAUTILUS SUBSIDIARY, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| CN-113759113-A | Urine protein marker for diagnosing medulloblastoma and application thereof | 首都医科大学附属北京天坛医院 | 2021-12-07 | — | — | CN | disclosed |
| EP-3897703-A2 | SERUM FREE INTRACELLULAR PATHOGEN VACCINE | Intervet International B.V. (NL) | 2021-10-27 | — | — | EP | disclosed |
| WO-2021049330-A1 | PROCESSING LIQUID, PROCESSING METHOD | 富士フイルム株式会社 | 2021-03-18 | — | — | WO | disclosed |
| WO-2020127941-A2 | SERUM FREE INTRACELLULAR PATHOGEN VACCINE | INTERVET INTERNATIONAL B.V. (NL) | 2020-06-25 | — | — | WO | disclosed |
| EP-0973801-B1 | GnRH ANTAGONISTS | FERRING BV (NL) | 2002-12-18 | — | — | EP | disclosed |
| US-6214798-B1 | POLYPEPTIDES | FERRING BV (NL) | 2001-04-10 | — | — | US | disclosed |
| EP-1003774-A1 | GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6 | FERRING B.V. (NL) | 2000-05-31 | — | — | EP | disclosed |
| EP-0973801-A1 | GnRH ANTAGONISTS | FERRING B.V. (NL) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998046634-A1 | GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6 | FERRING B.V. (NL) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998046635-A1 | GnRH ANTAGONISTS | FERRING BV (NL) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095275-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABELS | MYCBP, FABP3, STUB1 | FOLH1 1058/4885GSR 3664/4885SLC6A5 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.